These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38180557)

  • 1. Remdesivir: treatment of COVID-19 in special populations.
    Molaei E; Molaei A; Hayes AW; Karimi G
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):3829-3855. PubMed ID: 38180557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compassionate use of remdesivir in children with COVID-19.
    Méndez-Echevarría A; Pérez-Martínez A; Gonzalez Del Valle L; Ara MF; Melendo S; Ruiz de Valbuena M; Vazquez-Martinez JL; Morales-Martínez A; Remesal A; Sándor-Bajusz KA; Cabañas F; Calvo C
    Eur J Pediatr; 2021 Apr; 180(4):1317-1322. PubMed ID: 33200304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
    Khazir J; Maqbool T; Mir BA
    Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neonates With SARS-CoV-2 Infection and Pulmonary Disease Safely Treated With Remdesivir.
    Saikia B; Tang J; Robinson S; Nichani S; Lawman KB; Katre M; Bandi S
    Pediatr Infect Dis J; 2021 May; 40(5):e194-e196. PubMed ID: 33847299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for liver enzyme elevation with remdesivir use in the treatment of paediatric COVID-19.
    Jinda T; Mizuno S; Tatami S; Kasai M; Ishida T
    J Paediatr Child Health; 2024 Jul; 60(7):299-302. PubMed ID: 38818963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects.
    Humeniuk R; Mathias A; Cao H; Osinusi A; Shen G; Chng E; Ling J; Vu A; German P
    Clin Transl Sci; 2020 Sep; 13(5):896-906. PubMed ID: 32589775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remdesivir Administration in COVID-19 Patients With Renal Impairment: A Systematic Review.
    Davoudi-Monfared E; Ahmadi A; Karimpour-Razkenari E; Shahrami B; Najmeddin F; Mojtahedzadeh M
    Am J Ther; 2022 Sep-Oct 01; 29(5):e520-e533. PubMed ID: 35984955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compassionate Use of Remdesivir in Children With Severe COVID-19.
    Goldman DL; Aldrich ML; Hagmann SHF; Bamford A; Camacho-Gonzalez A; Lapadula G; Lee P; Bonfanti P; Carter CC; Zhao Y; Telep L; Pikora C; Naik S; Marshall N; Katsarolis I; Das M; DeZure A; Desai P; Cao H; Chokkalingam AP; Osinusi A; Brainard DM; Méndez-Echevarría A
    Pediatrics; 2021 May; 147(5):. PubMed ID: 33883243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes and safety of remdesivir in hospitalized individuals with COVID-19, with or without severe renal impairment.
    Chang MC; Wu PF; Ho YC; Lin WY; Wu CY; Liu SY; Liu CJ; Lin YT
    J Infect Public Health; 2024 Jul; 17(7):102460. PubMed ID: 38820894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remdesivir for the treatment of COVID-19.
    Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014962. PubMed ID: 34350582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Remdesivir in the Management of COVID-19: A Systematic Review on Current Evidences.
    Nasir M; Talha KA; Islam T; Saha SK; Selina F; Parveen RA
    Mymensingh Med J; 2020 Apr; 29(2):481-487. PubMed ID: 32506110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Remdesivir in children with COVID-19: report of an Italian multicenter study.
    Romani L; Roversi M; Bernardi S; Venturini E; Garazzino S; Donà D; Krzysztofiak A; Montagnani C; Funiciello E; Calò Carducci FI; Marabotto C; Castagnola E; Salvini F; Lancella L; Lo Vecchio A; Galli L; Castelli Gattinara G;
    Ital J Pediatr; 2024 Feb; 50(1):32. PubMed ID: 38413992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real life experience on the use of Remdesivir in patients admitted to COVID-19 in two referral Italian hospital: a propensity score matched analysis.
    Veronese N; Di Gennaro F; Frallonardo L; Ciriminna S; Papagni R; Carruba L; Agnello D; De Iaco G; De Gennaro N; Di Franco G; Naro L; Brindicci G; Rizzo A; Bavaro DF; Garlisi MC; Santoro CR; Signorile F; Balena F; Mansueto P; Milano E; Giannitrapani L; Fiordelisi D; Mariani MF; Procopio A; Lattanzio R; Licata A; Vernuccio L; Amodeo S; Guido G; Segala FV; Barbagallo M; Saracino A
    Sci Rep; 2024 Apr; 14(1):9303. PubMed ID: 38654033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032.
    Brooks KM; Baltrusaitis K; Clarke DF; Nachman S; Jao J; Purswani MU; Agwu A; Beneri C; Deville JG; Powis KM; Stek AM; Eke AC; Shapiro DE; Capparelli E; Greene E; George K; Yin DE; Jean-Philippe P; Chakhtoura N; Bone F; Bacon K; Johnston B; Reding C; Kersey K; Humeniuk R; Best BM; Mirochnick M; Momper JD;
    J Infect Dis; 2024 Oct; 230(4):878-888. PubMed ID: 38839047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness.
    Mechineni A; Kassab H; Manickam R
    Expert Opin Drug Saf; 2021 Nov; 20(11):1299-1307. PubMed ID: 34338121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
    Gottlieb RL; Vaca CE; Paredes R; Mera J; Webb BJ; Perez G; Oguchi G; Ryan P; Nielsen BU; Brown M; Hidalgo A; Sachdeva Y; Mittal S; Osiyemi O; Skarbinski J; Juneja K; Hyland RH; Osinusi A; Chen S; Camus G; Abdelghany M; Davies S; Behenna-Renton N; Duff F; Marty FM; Katz MJ; Ginde AA; Brown SM; Schiffer JT; Hill JA;
    N Engl J Med; 2022 Jan; 386(4):305-315. PubMed ID: 34937145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020.
    Rocca E; Gauffin O; Savage R; Vidlin SH; Grundmark B
    Drug Saf; 2021 Sep; 44(9):987-998. PubMed ID: 34374967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.
    Humeniuk R; Mathias A; Kirby BJ; Lutz JD; Cao H; Osinusi A; Babusis D; Porter D; Wei X; Ling J; Reddy YS; German P
    Clin Pharmacokinet; 2021 May; 60(5):569-583. PubMed ID: 33782830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remdesivir for Adults With COVID-19 : A Living Systematic Review for American College of Physicians Practice Points.
    Wilt TJ; Kaka AS; MacDonald R; Greer N; Obley A; Duan-Porter W
    Ann Intern Med; 2021 Feb; 174(2):209-220. PubMed ID: 33017170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis.
    Piscoya A; Ng-Sueng LF; Parra Del Riego A; Cerna-Viacava R; Pasupuleti V; Roman YM; Thota P; White CM; Hernandez AV
    PLoS One; 2020; 15(12):e0243705. PubMed ID: 33301514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.